Sarcopenia is defined as an age-associated loss of skeletal muscle function and muscle mass and is common in older adults. Sarcopenia as a disease is currently of interest not only to orthopedists and surgeons but also to internists, endocrinologists, rheumatologists, cardiologists, diabetologists, gynaecologists, geriatricians and paediatricians. In cooperation with the 5th Internal Medicine Clinic, we, as a unit of clinical research, aimed to describe a sarcopenic specific miRNA expression profile for disease diagnostics and classification of the severity of muscle performance deterioration. This study included a total of 80 patients (age 55-86 years) hospitalized at the V. Internal medicine clinic of LFUK and UNB with different severity of muscle performance deterioration. The study participants were evaluated and classified according to short physical performance battery score (SPPB). In this study, we investigated the role of circulating miRNAs in sarcopenia in the elderly. We hypothesized that sarcopenia effects the expression of muscle tissue-specific miRNAs (MyomiRNAs), which could be potentially reflected in the blood plasma miRNA expression profile. The expression of specific circulating miRNAs in patients with different muscle performances was analyzed. Patients' blood plasma was evaluated for the expression of myomiRNAs: miRNA-29a, miRNA-29b, miRNA-1, miRNA-133a, miRNA-133b, miRNA-206, miRNA-208b and miRNA-499, and the data were correlated with diagnostic indicators of the disease. We showed a specific sarcopenia miRNA profile that could be considered a possible biomarker for the disease. Patients with low muscle performance showed increased miRNA-1, miRNA-29a and miRNA-29b expression and decreased for the miRNA-206, miRNA-133a, miRNA-133b, miRNA-208b and miRNA-499 expression. We show that the severity of muscle performance deterioration in sarcopenia correlates with specific miRNA expression. We also propose the profile of miRNAs expression in blood plasma as a specific biomarker for sarcopenia diagnostics. Future clinical studies will be necessary to eventually naturally have to elucidate the underlined molecular mechanism responsible for specific miRNAs expression in sarcopenia pathology and progression of the disease.

Institute of Pharmacology and Clinical Pharmacology Faculty of Medicine Comenius University Bratislava Slovak Republic

See more in PubMed

BIOLO G, CEDERHOLM T, MUSCARITOLI M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr. 2014;33:737–748. https://doi:10.1016/j.clnu.2014.03.007 . PubMed DOI

BJÖRKMAN M, JYVÄKORPI SK, STRANDBERG TE, PITKÄLÄ KH, TILVIS RS. Sarcopenia indicators as predictors of functional decline and need for care among older people. J Nutr Health Aging. 2019;23:916–922. doi: 10.1007/s12603-019-1280-0. PubMed DOI

BROWN D, GOLJANEK-WHYSALL K. microRNAs: Modulators of the underlying pathophysiology of sarcopenia? Ageing Res Rev. 2015;24:263–273. https://doi:10.1016/j.arr.2015.08.007 . PubMed DOI

CHEN JF, MANDEL EM, THOMSON JM, WU Q, CALLIS TE, HAMMOND SM, CONLON FL, WANG DZ. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006;38:228–233. https://doi:10.1038/ng1725 . PubMed DOI PMC

CUI S, LI L, MUBAROKAH SN, MEECH R. Wnt/β-catenin signaling induces the myomiRs miR-133b and miR-206 to suppress IPax7 and induce the myogenic differentiation program. J Cell Biochem. 2019;120:12740–12751. https://doi:10.1002/jcb.28542 . PubMed DOI

DENT E, MORLEY JE, CRUZ-JENTOFT AJ, ARAI H, KRITCHEVSKY SB, GURALNIK J, BAUER JM, PAHOR M, CLARK BC, CESARI M, RUIZ J, SIEBER CC, AUBERTIN-LEHEUDRE M, WATERS DL, VISVANATHAN R, LANDI F, VILLAREAL DT, FIELDING R, WON CW, THEOU O, MARTIN FC, DONG B, WOO J, FLICKER L, FERRUCCI L, MERCHANT RA, CAO L, CEDERHOLM T, RIBEIRO SML, RODRÍGUEZ-MAÑAS L, ANKER SD, LUNDY J, GUTIÉRREZ ROBLEDO LM, BAUTMANS I, APRAHAMIAN I, SCHOLS JMGA, IZQUIERDO M, VELLAS B. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging. 2018;22:1148–1161. https://doi:10.1007/s12603-018-1139-9 . PubMed DOI

DIONYSSIOTIS Y. Sarcopenia in the elderly. Eur Endocrinol. 2019;15:13–14. https://doi:10.17925/EE.2019.15.1.13 . PubMed DOI PMC

ETHGEN O, BEAUDART C, BUCKINX F, BRUYÈRE O, REGINSTER JY. The future prevalence of sarcopenia in Europe: a claim for public health action. Calcif Tissue Int. 2017;100:229–234. https://doi:10.1007/s00223-016-0220-9 . PubMed DOI PMC

GRECO EA, PIETSCHMANN P, MIGLIACCIO S. Osteoporosis and sarcopenia increase frailty syndrome in the elderly. Front Endocrinol. 2019;10:255. https://doi:10.3389/fendo.2019.00255 . PubMed DOI PMC

HORAK M, NOVAK J, BIENERTOVA-VASKU J. Muscle-specific microRNAs in skeletal muscle development. Dev Biol. 2016;410:1–13. https://doi:10.1016/j.ydbio.2015.12.013 . PubMed DOI

HU Z, KLEIN JD, MITCH WE, ZHANG L, MARTINEZ I, WANG XH. MicroRNA-29 induces cellular senescence in aging muscle through multiple signaling pathways. Aging. 2014;6:160. https://doi:10.18632/aging.100643 . PubMed DOI PMC

IANNONE F, MONTESANTO A, CIONE E, CROCCO P, CAROLEO MC, DATO S, ROSE G, PASSARINO G. Expression patterns of muscle-specific miR-133b and miR-206 correlate with nutritional status and sarcopenia. Nutrients. 2020;12:297. https://doi:10.3390/nu12020297 . PubMed DOI PMC

KIM HK, LEE YS, SIVAPRASAD U, MALHOTRA A, DUTTA A. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol. 2006;174:677–687. https://doi:10.1083/jcb.200603008 . PubMed DOI PMC

SAGGINI R, CARMIGNANO SM, COSENZA L, PALERMO T, BELLOMO R. Sarcopenia in Chronic Illness and Rehabilitative Approaches. Frailty and Sarcopenia - Onset, Development and Clinical Challenges. 2017 https://doi:10.5772/intechopen.70223 . DOI

SIRACUSA J, KOULMANN N, BANZET S. Circulating myomiRs: a new class of biomarkers to monitor skeletal muscle in physiology and medicine. J Cachexia Sarcopenia Muscle. 2018;9:20–27. https://doi:10.1002/jcsm.12227 . PubMed DOI PMC

SOUSA-VICTOR P, MUÑOZ-CÁNOVES P. Regenerative decline of stem cells in sarcopenia. Mol Aspects Med. 2016;50:109–117. https://doi:10.1016/j.mam.2016.02.002 . PubMed DOI

Van ROOIJ E, QUIAT D, JOHNSON BA, SUTHERLAND LB, QI X, RICHARDSON JA, KELM RJ, JR, OLSON EN. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell. 2009;17:662–673. https://doi:10.1016/j.devcel.2009.10.013 . PubMed DOI PMC

YANAI K, KANEKO S, ISHII H, AOMATSU A, ITO K, HIRAI K, OOKAWARA S, ISHIBASHI K, MORISHITA Y. MicroRNAs in sarcopenia: a systematic review. Front Med. 2020;7:180. https://doi:10.3389/fmed.2020.00180 . PubMed DOI PMC

YU H, LU Y, LI Z, WANG Q. microRNA-133: expression, function and therapeutic potential in muscle diseases and cancer. Curr Drug Targets. 2014;15:817–828. https://doi:10.2174/1389450115666140627104151 . PubMed DOI

YEN PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001;81:1097–1142. https://doi:10.1152/physrev.2001.81.3.1097 . PubMed DOI